Identification and structure–activity relationships of a new series of Melanocortin-4 receptor antagonists
摘要:
The identification and optimization of a series of acylguanidine-based melanocortin-4 receptor antagonists is discussed. (C) 2006 Elsevier Ltd. All rights reserved.
This invention provides compounds and methods for treating melanocortin receptor associated disorders, such as weight loss disorders including cachexia resulting from cancer and other chronic illnesses. The compounds are represented by formula I:
1
wherein X is oxygen or sulfur; G is G1 or G2:
2
L
1
, L
2
, L
3
and Q are linker groups, and Rings A, B and C, and R
1
-R
14
are described in the specification. The compounds are antagonists of melanocortin receptors.